NEW YORK (GenomeWeb News) – Trovagene this week filed a shelf registration with the US Securities and Exchange Commission for the public offering of up to $150 million in securities from time to time.

A spokesperson for the San Diego-based molecular diagnostic firm said the filing is associated with a public offering that the company made in the spring of 2012 when it began trading its stock on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.